Annovis Bio, Inc.

NYSE ANVS

Annovis Bio, Inc. Capital Expenditure for the Trailing 12 Months (TTM) ending September 30, 2024

Annovis Bio, Inc. Capital Expenditure is NA for the Trailing 12 Months (TTM) ending September 30, 2024. Capital expenditure is cash spent on acquiring or maintaining fixed assets, such as property, plants, and equipment (PP&E).

Key data

Date	Capital Expenditure	Free Cash Flow	Depreciation And Amortization	Deferred Income Tax

NYSE: ANVS

Annovis Bio, Inc.

CEO	Dr. Maria L. Maccecchini Ph.D.
IPO Date	Jan. 29, 2020
Location	United States
Headquarters	1055 Westlakes Drive
Employees	6
Sector	Healthcare
Industries Pharmaceuticals 3D Printing Artificial Intelligence (AI) Biotechnology Clinical Trials Personal Care Robotics Vaccines

Description

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's disease, as well as is in clinical trials for Alzheimer's disease in Down Syndrome and other chronic neurodegenerative disorders. It is also developing ANVS405 for protecting the traumatic brain injury and stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania.

Key trends

Past 5 years